Investing in Spruce Biosciences (Nasdaq: SPRB) involves substantial operational, clinical, and financial risks that are characteristic of clinical-stage biotechnology equities. The foremost risk is clinical trial failure; drug candidates must undergo rigorous multi-phase testing, and any failure to achieve statistically significant primary or secondary efficacy endpoints—or the emergence of adverse safety profiles—can severely damage the company's valuation. Additionally, Spruce Biosciences faces significant regulatory approval risks, as commercialization requires stringent clearances from the U.S. Food and Drug Administration (FDA) and international regulatory bodies, with no guarantee of approval. As a pre-revenue biotechnology developer, the company experiences continuous operational cash burn and relies on capital markets to fund its research programs. This creates ongoing dilution risk through secondary equity offerings, warrant exercises, or reverse stock splits. Furthermore, SPRB stock suffers from high price volatility, low trading liquidity at times, intense competition from rival pharmaceutical developers targeting similar rare diseases, and risks associated with successfully scaling manufacturing processes for complex biological drug products.